Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dinesh Jain

Internal Medicine Palos Heights, IL Medical Doctor

NPI 1255330361 CMS profile 147985

7880 W College Dr, Palos Heights, IL 60463

Open in the dashboard

General payments

$8,833

459 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dinesh Jain of Palos Heights, IL is reported in the CMS Open Payments database as having received $8,833 across 459 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $905 46
2024 General $603 28
2023 General $533 31
2022 General $1,289 60
2021 General $2,231 109
2020 General $1,797 98
2019 General $1,475 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dinesh Jain
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dinesh Jain were reported at $905. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dinesh Jain Internal Medicine median Middle half National median
2019 $1,475 $159 $48–$570 $163
2020 $1,797 $119 $33–$402 $114
2021 $2,231 $135 $37–$521 $132
2022 $1,289 $141 $42–$496 $149
2023 $533 $149 $45–$519 $160
2024 $603 $154 $47–$537 $164
2025 $905 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,158 105 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $781 46 payments
  3. Pfizer Inc. $701 29 payments
  4. Merck Sharp & Dohme Corporation $541 38 payments
  5. Lilly USA, LLC $530 27 payments
  6. Janssen Pharmaceuticals, Inc $526 26 payments
  7. Amgen Inc. $385 15 payments
  8. Novo Nordisk Inc $382 25 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $319 18 payments
  10. Novartis Pharmaceuticals Corporation $286 16 payments
  11. Other $2,225 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,766 457 payments
  2. Education $67 2 payments
Products named General payments · program years 2019–2025
  1. BREZTRI $1,010 48 payments
  2. FARXIGA $804 34 payments
  3. JARDIANCE $588 37 payments
  4. XARELTO $526 26 payments
  5. ELIQUIS $401 13 payments
  6. JANUVIA $393 27 payments
  7. STEGLUJAN $345 23 payments
  8. STEGLATRO $297 20 payments
  9. MOUNJARO $273 12 payments
  10. SYMBICORT $257 15 payments
  11. Other $6,509 352 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 135 drugs

Part D claims

9,061

Median for Internal Medicine: 777

Drug cost

$597,386

Median for Internal Medicine: $73,373

Branded share of claims

20.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 396 $143,994
Trulicity Dulaglutide Brand 38 $56,076
Jardiance Empagliflozin Brand 35 $36,747
Ozempic Semaglutide Brand 27 $36,277
Xarelto Rivaroxaban Brand 76 $32,754
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 42 $31,829
Farxiga Dapagliflozin Propanediol Brand 24 $18,763
Myrbetriq Mirabegron Brand 22 $18,004
Breo Ellipta Fluticasone/Vilanterol Brand 32 $17,246
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 22 $16,785

The 10 drugs with the highest cost, of 135 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$128,706

Medicare's payments for the services billed

Medicare patients

316

Average age 78

Services billed

1,791

174 women, 142 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 47%
Ischemic heart disease 45%
Chronic kidney disease 42%
Heart failure 36%
Atrial fibrillation 33%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $175
$175 22 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $115
$115 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $98
$98 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $68
$68 24 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

459 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record